← Leaderboards
Sujan Shresta
La Jolla Institute For Immunology
$16,730,144
Attributed
$17,982,382
Total exposure
13
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,982,382 · 13
By mechanism
R01$10,414,657 · 4
R21$2,048,761 · 4
U01$1,779,809 · 1
U54$1,755,275 · 1
R56$1,207,992 · 2
R24$775,888 · 1
Top collaborators
- David D Lo2 shared
- Alex Y Strongin2 shared
- Alexey V Terskikh2 shared
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionDengue VirusMediatingVirusResponseSerotypingDengueVaccinesT-LymphocyteBaseImmune ResponseFlavivirusImmunizationPathogenesisImmunityVirus DiseasesT Cell ResponseMouse ModelAntibodiesImmuneDengue InfectionCellsPreventProduction
Grant awards (35)
A novel strategy for vaccine-induced protection against maternal-to-fetal transmission of Zika virus$873,588
R01 · FY2025 · AI · contact PI
Next Generation Crispr Ready, HLA Class I and II Transgenic Mouse Platform$775,888
R24 · FY2025 · OD · contact PI
Development of a Replicon RNA-based Vaccine against Dengue and Zika$721,849
R01 · FY2025 · AI · contact PI
Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis$551,334
R01 · FY2025 · AI · contact PI
A novel strategy for vaccine-induced protection against maternal-to-fetal transmission of Zika virus$894,640
R01 · FY2024 · AI · contact PI
Development of a Replicon RNA-based Vaccine against Dengue and Zika$721,849
R01 · FY2024 · AI · contact PI
Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis$568,385
R01 · FY2024 · AI · contact PI
Development of a Replicon RNA-based Vaccine against Dengue and Zika$721,849
R01 · FY2023 · AI · contact PI
Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis$568,385
R01 · FY2023 · AI · contact PI
Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis$725,399
R01 · FY2022 · AI · contact PI
Development of a Replicon RNA-based Vaccine against Dengue and Zika$712,699
R01 · FY2022 · AI · contact PI
Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis$725,399
R01 · FY2021 · AI · contact PI
Development of a Replicon RNA-based Vaccine against Dengue and Zika$712,699
R01 · FY2021 · AI · contact PI
Development of a Replicon RNA-based Universal Vaccine against Dengue and Zika$761,992
R56 · FY2020 · AI · contact PI
IRF-3/5/7-Independent Antiviral Immunity$535,078
R01 · FY2019 · AI · contact PI
Vaginal Adaptive Immunity Against Zika Virus$225,000
R21 · FY2019 · AI · contact PI
IRF-3/5/7-Independent Antiviral Immunity$442,500
R01 · FY2018 · AI · contact PI
Vaginal Adaptive Immunity Against Zika Virus$270,000
R21 · FY2018 · AI · contact PI
Targeting Angiogenesis Pathways for Therapeutic Protection against Dengue$225,000
R21 · FY2018 · AI · contact PI
IRF-3/5/7-Independent Antiviral Immunity$54,004
R01 · FY2018 · AI · contact PI
IRF-3/5/7-Independent Antiviral Immunity$442,500
R01 · FY2017 · AI · contact PI
Targeting Angiogenesis Pathways for Therapeutic Protection against Dengue$270,000
R21 · FY2017 · AI · contact PI
Host-pathogen interactions in ZIKV infection leading to microcephaly$236,250
R21 · FY2017 · NS
IRF-3/5/7-Independent Antiviral Immunity$442,500
R01 · FY2016 · AI · contact PI
Host-pathogen interactions in ZIKV infection leading to microcephaly$307,250
R21 · FY2016 · NS
T cell response to Dengue virus serotype 3 in mice and humans$440,609
U54 · FY2013 · AI · contact PI
T cell response to Dengue virus serotype 3 in mice and humans$406,874
U54 · FY2012 · AI · contact PI
Pathogenic Role of Antibodies to Dengue Virus$446,000
R56 · FY2011 · AI · contact PI
T cell response to Dengue virus serotype 3 in mice and humans$263,363
U54 · FY2011 · AI · contact PI
Mucosal Vaccination Against Dengue Virus Infection$878,792
U01 · FY2010 · AI · contact PI
T cell response to Dengue virus serotype 3 in mice and humans$458,665
U54 · FY2010 · AI · contact PI
Mucosal Vaccination Against Dengue Virus Infection$901,017
U01 · FY2009 · AI · contact PI
T cell response to Dengue virus serotype 3 in mice and humans$185,764
U54 · FY2009 · AI · contact PI
T Cell Response to Dengue Virus$231,761
R21 · FY2008 · AI · contact PI
T Cell Response to Dengue Virus$283,500
R21 · FY2007 · AI · contact PI